Special Issue

Exosome and Biotherapeutic Strategies for Dermatological and Oncological Skin Complications

Message from the Guest Editors

This Special Issue explores the expanding role of exosomes and biotherapeutic strategies in the treatment and regeneration of the skin across a wide spectrum of dermatologic conditions. As cell-free agents with regenerative, anti-inflammatory, and immunomodulatory properties, exosomes hold great promise for applications ranging from wound healing and scar remodeling to aesthetic skin rejuvenation and the management of inflammatory dermatoses. In recent years, their use has also gained attention in supporting skin recovery following energy-based procedures such as laser therapy. Particular focus is also given to the role of exosomes in managing oncologic skin complications, including adverse cutaneous reactions caused by chemotherapy, radiotherapy, targeted therapies (e.g., EGFR and BRAF/MEK inhibitors), and immunotherapies. We invite original research articles, clinical case reports, and reviews that examine therapeutic mechanisms, safety, delivery strategies, and treatment outcomes. Interdisciplinary contributions from dermatology, oncology, and regenerative medicine are especially encouraged to foster integrated, patient-centered care models.

Guest Editors

Dr. Lidia Maiewska

ESME Clinic, ul. Lwowska 1/U16, 30-548 Kraków, Poland

Dr. Jacek M. Kijowski

Bank Komórek MCB, Małopolskie Centrum Biotechnologii, Uniwersytet Jagielloński, ul. Gronostajowa 7a, 30-387 Kraków, Poland

Deadline for manuscript submissions

25 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/244350

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

